The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Current Cardiology Reports"
DOI: 10.1007/s11886-019-1103-2
Abstract: Purpose of ReviewTo review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice.Recent FindingsDespite widespread use of statins for lipid lowering, many patients at high cardiovascular risk… read more here.
Keywords: new face; risk; pcsk9 inhibitors; face hyperlipidemia ... See more keywords